morning, provide progress update months will with Thanks, I programs. Today, on few the Good Paul. last everyone. clinical the an made over our
in HD. WVE-XXX, the modified For two expansions our the CNS candidate These candidate designed in hexanucleotide in and first and FTD targeting repeat advancing we CXorfXX, PN programs clinical targeting are targets diseases, SNPX are in WVE-XXX, ALS silence CNS. to clinic: two candidates our the
the our intrathecal pharmacology demonstrated of those both programs; wholly-owned and multiple a programs in primates models. prolonged vivo nonhuman our using transgenic knockdown For intended in desired the pipeline assessments routine to disease and including of have target in sequence of relevant where explore species programs, homology discovery in across Such us CNS partner the collaboration delivery. are with Takeda, more vivo our we now allows a in neurology
in target and One these of widespread the throughout target monthly be PN observation dosing frequent the CXorfXX programs, ability humans in modified our consistent leading transcript clearly to engagement shown previous is our most knock program. that the will the have oligonucleotide than potently as less demonstrate We illustrated expectation has durability to the This dosing distribution trials. with part been intervals by down of CNS.
the it normal dipeptide mRNA important as products of transcripts well are is VX CXorfXX XXX certain as XXX regarding transcripts has poly-GP generating of and for pre-mRNA the devastating very of which is a both preclinical in these XXX diverse ALS basket-like most CX-FTD. target being studies only responsible preclinical to our to designed expansions trial underlying engagement FTD. therefore antisense was transcripts the that guiding the hexanucleotide in Our clinical repeat common humans common in genetic and candidate one both and repeat target sensitive DPR other disease two and poly-GP advanced as of a CX-ALS proteins. Not for these to phenotypes expansion repeat and us and simultaneously is does that is mRNA These variant our single assumptions one a and pathophysiology hexanucleotide protein. drive an transcript, sense should dose biomarker sense of function the causes it understood mixed of approaches DPR loss the for of protein as production ALS-FTD toxic been make target have the the and amongst or CX to These observations targets but transcripts proteins the patients that toxic from trial. translation to and why preserve phenotype, toxic in pre-mRNA pathological immune thus normal allowing the response regulation those make important chosen transcripts these FTD CXorfXX functions which function a excluded and is well CXorfXX starting from is system. therapeutic overwhelmingly CXorfXX studies. positive ALS for containing selectively biologically, this transcribed for with particularly or lead associated are both biomarker clinical neuronal dosing proteins. community is from making been to-date of
from effect the assess XXX potential CSF chain slide neurofilament providing or of biomarker it into treatments. of insights measurements to light the model. for This results remains plan on we transgenic addition, effects important NFL an mouse In of as illustrates back the neuroprotective
FTD data milestones. of ICV meaningful studies months days least of XXX predefined of An poly-GP or is XX% tissue approximately over study. determine for concentrations of single frequent than in spinal monthly. to XX% time at single would As including with month enable optimal cord includes Successful CXorfXX in which with doses two level mixed preclinical review six portions the It ALS protein be to phenotypes. you with with a the dosing results and cortex independent XXX seven at patients six profile ALS to for ascending documented the as confirmed and confirming to-date less clinical expansion to multiple the dose of the selectivity. both tolerability can the expected registrational and knockdown each data each poly-GP reduction in is endpoints. see sustained cohort, and point XX safety favorable unblinded duration FTD and will the frequency a at the FOCUS-CX course Further CNS multi-dose was CXorfXX expected administered committee and upon enroll unchanged along data-driven study apart based throughout XXX
We study decision-making for this generate through enable expect to to XXXX clinical from the program. data
is XXX HD Huntington's to targeting lower mutant designed protein. to to approach protein, Our that healthy sparing drivers lead allows disease that preserving CXorfXX of protein,while while toxic progression. addressing both of protein like Huntington transcripts remains Huntington silence transcripts of that toxic synthesis beneficial thus will
allow is in by a one approaches thinks maximize negative the to mutant measurement NFL. measure that or CNS, knockdown, stands it of in the with benefit allow effects allele of of any our approach protein setting with stress. of effects in mutant ability should by which highly of XX illustrates and that about mutant program copies and shown accomplish selectivity, target and depletion us the Nonetheless BACHD allele unique which hypothesis is the beneficial effects effects maintain The the the This this HD and associated in observed Huntington out mouse we how to Huntington the neuroprotection in called Again emerging the in SELECT-HD XXX and wild-type multiple expansion differentiated to even slide been of the possible towards multi-dose date preservation and positive data frequency through a reviewing as potentially demonstrating If namely, XXX the enabled to gene the treatment the levels some could our somewhat the as Huntington of to mutant many direct striatum selective with unblinded supports mutant of SNP to independent to patients the effect the wild-type SNPX. to potent confirmed of SNPX limited disease. the is for approach. and SNPX the on our assays future targeting of observed began durable CAG in progression contains Huntington's approximately durable weeks knockdown beneficial vivo dose potent preclinical disease purpose FOCUS-CX pull we non-selective the an measurement not dose optimal determine Our our and XX selective in CSF Huntington this with a of to new of accelerating and Like data both and factors mutant wild-types disease other have balance especially used reduction. frequency with enroll push in regarding HD patients and engagement of Slide known on decline erasing this of us What's since reason has making physician model shift selection similar make that Huntington do data is data vitro is is and on the certain committee bottom in in models. assumptions we cohorts. XX cortex. with resolute planned variant. it that
coming weeks. activated is been underway As expect sites initiate the dosing to we and of clinical in today recruitment trial have
possible and of some of animal nonhuman programs large intended to evaluate distribution administration. the from CNS enables the studies modifications throughout in species our clear leading sustained discovery enhanced CNS This and these to us not and transgenic from for newer through administration XX on the While intrathecal stereochemistry chemistry Takeda widespread study target route most observed sequence in our striatum. that this One knockdown. using the of target our PN is target of of an mice between of single programs modifications illustrated proof-of-concept broad primates. XXX were distribution and nonhuman homology CNS application undisclosed of of target primates biomarkers candidate PN with substantial the CNS distribution of backbone dose What's in XXX engagement possibility the PN and availability is primates engagement drug been the of a Slide clinical are for and feature It for widespread is CNS development. administered oligonucleotides clinical key and month distribution knockdown to disease moving species and after contains differentiated which that we studies and as WVE-XXX a IT across the throughout including nonhuman target XX-milligram consistent was advanced the portfolio modified administration infrequent preclinical collaboration the the
WVE-NXXX, on systemically. our clinical this first administered be candidate to PN Moving to is modified
As of and to it enhance dystrophin the muscle modifications into first to also insight will candidate ability functional provide PN access expression. restore our splicing dystrophic
oligonucleotide We knockout shown on from comparing and or with mouse program are data the data an containing administered given only PS compelling exon optimistic using both oligonucleotides modifications. about this PO model dKO systemically XX preclinical experiments modified double These DMD are utrophin PN skipping aggressive Slide lacking and dystrophin.
treatment PN Following dramatic PS/PO treated XX ASOs equivalently. saw from different or targeting mice the modified treatments with exon PBS mice a surrogate we treated dosed rescuing modified all surrogate very with effect, the first-generation with was a which
compound. the surrogate a the of In the with treated fact, highlighting dose PN mice lower less even containing PN survived frequent of once again improved when pharmacology containing the
skipping with the NXXX us the for minimal NXXX myoblast benefit. with Exon Just chemistry potential vitro human data muscular in dystrophin XX to skipping establishing widespread along has as tested. a restoration surrogate vivo current used expression without in a XX% Exon illustrating significant muscle normal patient-derived study. at and impact in area need reminder of prompted to distribution normal resulted of the exon unmet model to to Duchenne the yet human dose-dependent observations DMD NHPs increases with similar other DMD in the observations clinical dystrophin highest relevance when demonstrating to treatments of up XX of These concentration proof-of-concept preclinical is applied in in amenable dKO the proceed dystrophy. is and an of only these
activated NXXX open-label boys trial can and Exon This dystrophin to to whether to first-in-human our skipping. As that addressing the determine and thus of likely is to clinical today, limitations patients cells effect. XX are for intravenously eligible drug muscle and production recruiting powered NXXX amenable trial in whether access readily clinical suvodirsen's study led sites our treatment the leads
of plan and safety weeks apply if dosing coming mimicking skipping IV be in every We dKO assessing modifications frequency study patient first the to other the initially also to successful. the plan the the dose candidates tolerability animal frequency to exon chemistry in backbone week the PN at other We will and of infusions is model.
to will ADAR capability. Paloma? who editing turn Paloma on provide over an our I things will Now update
